NCT01616654

Dose Range Study of CD5789 in Acne Vulgaris

A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 304 (actual)
• Sponsor: Galderma R&D · Industry
• Sex: All
• Age: 12 Years – 35 Years
• Healthy volunteers: Not accepted

Summary

To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.

Conditions

• Acne Vulgaris

Interventions

Type	Name	Description
DRUG	CD5789 25 µg/g cream	CD5789 25 µg/g cream applied once daily
DRUG	CD5789 50 µg/g cream	CD5789 50 µg/g cream applied once daily
DRUG	CD5789 100 µg/g cream	CD5789 100 µg/g cream applied once daily
DRUG	Tazarotene 0.1% gel	Tazarotene 0.1% gel applied once daily
DRUG	Vehicle cream	Vehicle cream applied once daily

Timeline

• Start date: 2012-06-20
• Primary completion: 2013-07-24
• Completion: 2014-06-12
• First posted: 2012-06-12
• Last updated: 2021-09-20
• Results posted: 2021-09-20

Locations

24 sites across 1 country: United States